Common diabetes drug may shield hearts during chemo
NCT ID NCT06491680
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. Forty women with breast cancer will take dapagliflozin daily alongside their chemo. Researchers will measure heart function and blood markers to see if the drug offers protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dapagliflozin (a diabetes drug)
- What this could lead to
- If it works, this could offer a simple way to prevent heart damage during breast cancer chemotherapy, improving long-term heart health.
- What could go wrong
- This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The drug may not provide significant heart protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Al demerdash hospital at oncology departement
RECRUITINGCairo, Cairo Governorate, 202, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?